Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P.

J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. Epub 2007 Dec 25.

PMID:
18159072
2.

HER2/neu in systemic therapy for women with breast cancer: a systematic review.

Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M.

Breast Cancer Res Treat. 2008 May;109(2):209-29. Epub 2007 Jul 17. Review.

PMID:
17636396
3.

[Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].

Nagykálnai T.

Magy Onkol. 2002;46(4):307-13. Epub 2003 Feb 1. Review. Hungarian.

4.

New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.

Gennari A, Pronzato P.

Clin Breast Cancer. 2008 Dec;8 Suppl 4:S179-83. doi: 10.3816/CBC.2008.s.015. Review.

PMID:
19158039
5.

HER-2 and topoisomerase II as predictors of response to chemotherapy.

Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B.

J Clin Oncol. 2008 Feb 10;26(5):736-44. doi: 10.1200/JCO.2007.15.4716. Review.

PMID:
18258981
6.

Predictive factors for anthracycline-based chemotherapy for human breast cancer.

Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S.

Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Review.

PMID:
19657712
7.
8.

Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.

Lemos Duarte I, da Silveira Nogueira Lima JP, Passos Lima CS, Deeke Sasse A.

Breast. 2012 Jun;21(3):343-9. doi: 10.1016/j.breast.2012.02.011. Epub 2012 Mar 15. Review.

PMID:
22425607
9.

[Anthracyclines in the adjuvant treatment of breast carcinoma: thirty years later].

Lopez M.

Clin Ter. 2006 Mar-Apr;157(2):165-77. Review. Italian.

PMID:
16817507
10.
11.

The predictive value of HER2 in breast cancer.

Piccart M, Lohrisch C, Di Leo A, Larsimont D.

Oncology. 2001;61 Suppl 2:73-82. Review.

PMID:
11694791
12.

Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.

Estévez LG, Muñoz M, Alvarez I, Fernández Y, García-Mata J, Ruiz-Borrego M, Tusquets I, Seguí MA, Rodríguez-Lescure A, Adrover E, Lluch A.

Cancer Treat Rev. 2007 Aug;33(5):474-83. Epub 2007 Jun 11. Review.

PMID:
17561350
13.

Predicting anthracycline benefit: have we made any progress?

Moretti E, Oakman C, Di Leo A.

Curr Opin Oncol. 2009 Nov;21(6):507-15. doi: 10.1097/CCO.0b013e328331a501. Review.

PMID:
19713842
14.

Adjuvant therapy for breast cancer.

Hennessy BT, Pusztai L.

Minerva Ginecol. 2005 Jun;57(3):305-26. Review.

PMID:
16166938
15.

Taxanes for adjuvant treatment of early breast cancer.

Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004421. Review.

PMID:
17943815
16.

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.

Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP.

J Natl Cancer Inst. 2008 Dec 17;100(24):1780-91. doi: 10.1093/jnci/djn414. Epub 2008 Dec 9. Review.

PMID:
19066278
17.

[Effectiveness of precautionary chemotherapy in gastric cancer].

Rimassa L, Campagnoli E, Biancofiore G.

Tumori. 2000 Sep-Oct;86(5 Suppl 2):S5-13. Review. Italian.

PMID:
11195303
18.

Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.

Pal SK, Childs BH, Pegram M.

Breast Cancer Res Treat. 2010 Jan;119(1):25-32. doi: 10.1007/s10549-009-0567-y. Review.

PMID:
19795206
19.

Anthracyclines in early-stage breast cancer: is it the end of an era?

Robson D, Verma S.

Oncologist. 2009 Oct;14(10):950-8. doi: 10.1634/theoncologist.2008-0070. Epub 2009 Jun 26. Review. Erratum in: Oncologist. 2009 Dec;14(12):1252.

20.

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Amir E, Ocaña A, Seruga B, Freedman O, Clemons M.

Cancer Treat Rev. 2010 Aug;36(5):410-5. doi: 10.1016/j.ctrv.2009.12.012. Epub 2010 Jan 25. Review.

PMID:
20100635

Supplemental Content

Support Center